HF
KLRS

HRT Financial’s Kalaris Therapeutics KLRS Stock Holding History

HRT Financial’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55K Buy
13,723
+2,106
+18% +$10.9K ﹤0.01% 3749
2026
Q1 		$67K Buy
+11,617
New +$103K ﹤0.01% 3415
2025
Q1 		– Sell
-1,373
Closed -$13K – 3592
2024
Q4 		$13K Buy
+1,373
New +$20.8K ﹤0.01% 2257
2023
Q1 		– Sell
-2,088
Closed -$246K – 3326
2022
Q4 		$246K Buy
+2,088
New +$354K ﹤0.01% 1842
2022
Q3 		– Sell
-1,893
Closed -$169K – 3634
2022
Q2 		$169K Buy
1,893
+1,291
+214% +$135K ﹤0.01% 2298
2022
Q1 		$93K Buy
+602
New +$120K ﹤0.01% 2676
2021
Q3 		– Sell
-3,486
Closed -$1.58M – 3862
2021
Q2 		$1.58M Buy
+3,486
New +$1.8M 0.01% 744

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial's KLRS Position: Q2 2026 in Review

HRT Financial increased its Kalaris Therapeutics (KLRS) stake by 18% in Q2 2026, buying an estimated $10.9K and bringing the position to 13,723 shares worth $55K. The position accounts for ﹤0.01% of the portfolio, ranked #3749.

HRT Financial first reported a position in KLRS in Q2 2021 and has held it in 7 quarters since. The position peaked at $1.58M in Q2 2021. 57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • HRT Financial held 13,723 shares of Kalaris Therapeutics worth $55K as of Q2 2026.
  • HRT Financial bought 2,106 Kalaris Therapeutics shares in Q2 2026, an estimated $10.9K.
  • Kalaris Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #3749 holding.
  • HRT Financial first reported a position in Kalaris Therapeutics in Q2 2021 and has held it in 7 quarters since.
  • HRT Financial's Kalaris Therapeutics position peaked at $1.58M in Q2 2021.
  • 57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.